Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Marie Michot, Franck Morschhauser, Silvia Ferrari, Judit Mészáros Jørgensen, Loretta Nastoupil, Emmanuel Bachy, Michael Pourdehnad, Akshay Sudhindra, Alev Akyol, Bérengère de Moucheron, Soraya Carrancio, Jessica Voetsch, Xirong Zheng, Julio C. Chavez

Blood (2024) 144 (Supplement 1): 869.

https://doi.org/10.1182/blood-2024-203163

Published: 2024

Journal Articles

GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study

Silvia Ferrari, Anna Maria Barbui, Gritti Giuseppe, Andrea Rossi, Anna Grassi, Francesco Ballardini, Monica Rondi, Chiara Pavoni, Paolo Fruscella, Andrea Gianatti, Alessandro Rambaldi

Blood (2024) 144 (Supplement 1): 3114.

https://doi.org/10.1182/blood-2024-208027

Published: 2024

Journal Articles

CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia

Blood (2024) 144 (Supplement 1): 2834.

https://doi.org/10.1182/blood-2024-206806

Published: 2024

Journal Articles

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Blood (2024) 144 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2024-207660

Published: 2024

Journal Articles

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Monica Rondi, Silvia Ferrari, Anna Maria Barbui, Andrea Rossi, Chiara Pavoni, Anna Grassi, Federico Lussana, Alessandro Rambaldi, Giuseppe Gritti

Blood (2023) 142 (Supplement 1): 2331.

https://doi.org/10.1182/blood-2023-189911

Published: 2023

Journal Articles

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage

Blood (2023) 141 (22): 2780–2783.

https://doi.org/10.1182/blood.2022017951

Published: 2023

Includes: Supplemental data

Journal Articles

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Soraya Carrancio, Wen-Chi Chou, Alberto Risueño, Carla Guarinos, Gonzalo Lopez, Jean-Marie Michot, Loretta J. Nastoupil, Julio Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo Giles, Antonio Pinto, Danielle Greenawalt, Daniel W. Pierce, Michael Pourdehnad

Blood (2022) 140 (Supplement 1): 6455–6457.

https://doi.org/10.1182/blood-2022-159585

Published: 2022

Journal Articles

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2022) 140 (Supplement 1): 4568–4569.

https://doi.org/10.1182/blood-2022-165448

Published: 2022

Journal Articles

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study

Alessandro Bosi, Bruno Fattizzo, Lorenzo Rizzo, Silvia Ferrari, Federico Lussana, Lorenza Maria Borin, Andrea Castelli, Paola Bianchi, Wilma Barcellini, Roberto Cairoli, Alfredo Molteni, Marta Riva

Blood (2022) 140 (Supplement 1): 6925–6926.

https://doi.org/10.1182/blood-2022-157430

Published: 2022

Journal Articles

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Blood (2022) 140 (Supplement 1): 10339–10340.

https://doi.org/10.1182/blood-2022-166788

Published: 2022

Journal Articles

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Giuseppe Gritti, Federico Lussana, Silvia Ferrari, Anna Maria Barbui, Francesco Landi, Giulia Quaresmini, Gianmaria Borleri, Muriel Paganessi, Chiara Pavoni, Elisa Gotti, Chiara Capelli, Josee Golay, Martino Introna, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 10325–10326.

https://doi.org/10.1182/blood-2022-170120

Published: 2022

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2021) 138 (Supplement 1): 472.

https://doi.org/10.1182/blood-2021-148703

Published: 2021

Journal Articles

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Jean-Marie Michot, Julio C. Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J Buchholz, Soraya Carrancio, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Blood (2021) 138 (Supplement 1): 3574.

https://doi.org/10.1182/blood-2021-147333

Published: 2021

Journal Articles

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Giuseppe Rossi, Henry Miles Prince, Constantine S. Tam, Matthew Ku, Catherine Thieblemont, Leslie L. Popplewell, Martin Wermke, Corinne Haioun, Nicole Wong Doo, Andreas Viardot, Andrés J M Ferreri, Silvia Ferrari, Hansen L. Wong, Priti Kadu, Gerhard Zugmaier, Yi Zeng, Alessandro Rambaldi

Blood (2021) 138 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2021-152822

Published: 2021

Journal Articles

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Armando Santoro, Alison J. Moskowitz, MD, Silvia Ferrari, MD, Carmelo Carlo-Stella, MD, Michelle A. Fanale, MD, Stephen Francis, Mariana Sacchi, MD, Kerry J. Savage, MDMSc

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137653

Published: 2020

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141236

Published: 2020

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2019) 134 (Supplement_1): 200.

https://doi.org/10.1182/blood-2019-125894

Published: 2019

Journal Articles

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Gilles Salles, MD PhD, Daniel J. Landsburg, MD, Giuseppe Gritti, MD PhD, Krish Patel, MD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD, William Townsend, MRCP,MDFRCPath, Silvia Ferrari, MD, Kate F. Stumpo, BA, Shilpi Katyayan, Cheryl Li, Harry Miao, MD, Igor Proscurshim, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5310.

https://doi.org/10.1182/blood-2019-125650

Published: 2019

Journal Articles

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Lydia Scarfo, MD, Silvia Ferrari, Annamaria Maria Frustaci, Monica Tani, Samantha Pozzi, MD, Eloise Scarano, Maria Colia, Pamela Ranghetti, Maurilio Ponzoni, MD, Paola Ronchi, MD, Andres JM Ferreri, MD, Paolo Ghia, MD PhD

Blood (2018) 132 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2018-99-113875

Published: 2018

NARROW

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study

CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ofatumumab Is Active and Safe in Patients with Relapsed/Refractory Splenic Marginal Zone Lymphoma (SMZL): Results from the Interim Analysis of an Italian Multicenter Phase 2 Study (MORE trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only